Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
The ongoing COVID-19 pandemic has raised concerns about the risk of SARS-CoV-2 infection. Vedolizumab is used to treat Crohn's disease (CD) and ulcerative colitis (UC) patients taking immunosuppressants or biologics. Eight RCTs involving 3,287 patients (1873 CD and 1415 UC) were analyzed. The rates of RTI and URTI were statistically higher in vedolizumab-treated patients compared to placebo. The number of LRTI was small in both treatment groups.
